1. Home
  2. NVCR vs HTH Comparison

NVCR vs HTH Comparison

Compare NVCR & HTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • HTH
  • Stock Information
  • Founded
  • NVCR 2000
  • HTH 1998
  • Country
  • NVCR Switzerland
  • HTH United States
  • Employees
  • NVCR N/A
  • HTH N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • HTH Major Banks
  • Sector
  • NVCR Health Care
  • HTH Finance
  • Exchange
  • NVCR Nasdaq
  • HTH Nasdaq
  • Market Cap
  • NVCR 1.9B
  • HTH 1.9B
  • IPO Year
  • NVCR 2015
  • HTH 2004
  • Fundamental
  • Price
  • NVCR $17.60
  • HTH $30.77
  • Analyst Decision
  • NVCR Buy
  • HTH Hold
  • Analyst Count
  • NVCR 7
  • HTH 2
  • Target Price
  • NVCR $32.43
  • HTH $33.00
  • AVG Volume (30 Days)
  • NVCR 1.4M
  • HTH 468.9K
  • Earning Date
  • NVCR 07-24-2025
  • HTH 07-24-2025
  • Dividend Yield
  • NVCR N/A
  • HTH 2.33%
  • EPS Growth
  • NVCR N/A
  • HTH 15.07
  • EPS
  • NVCR N/A
  • HTH 1.97
  • Revenue
  • NVCR $621,711,000.00
  • HTH $1,208,822,000.00
  • Revenue This Year
  • NVCR $5.56
  • HTH N/A
  • Revenue Next Year
  • NVCR $9.19
  • HTH $1.36
  • P/E Ratio
  • NVCR N/A
  • HTH $15.71
  • Revenue Growth
  • NVCR 18.27
  • HTH 2.13
  • 52 Week Low
  • NVCR $14.17
  • HTH $26.67
  • 52 Week High
  • NVCR $34.13
  • HTH $35.32
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 49.74
  • HTH 52.06
  • Support Level
  • NVCR $16.81
  • HTH $30.92
  • Resistance Level
  • NVCR $18.59
  • HTH $32.16
  • Average True Range (ATR)
  • NVCR 0.74
  • HTH 0.53
  • MACD
  • NVCR 0.08
  • HTH 0.04
  • Stochastic Oscillator
  • NVCR 56.18
  • HTH 50.34

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About HTH Hilltop Holdings Inc.

Hilltop Holdings Inc is a Dallas-based financial holding company. The Company has two primary business units, PCC (banking and mortgage origination) and Securities Holdings (broker-dealer). The banking segment includes the operations of the Bank. The banking segment provides business and consumer banking services from offices located throughout Texas and generates revenue from its portfolio of earning assets. The broker-dealer segment includes the operations of Securities Holdings, which operates through its wholly owned subsidiaries Hilltop Securities, Asset Managment LLC, etc. The broker-dealer segment generates a majority of its revenues from fees and commissions earned from investment advisory and securities brokerage services. Majority of revenue is from Banking Segment.

Share on Social Networks: